Drug Profile
Olvimulogene nanivacirepvec - Genelux Corporation
Alternative Names: GL-ONC1; GLV-1h68; Olvi-Vec - Genelux CorporationLatest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Genelux Corporation
- Developer Genelux Corporation; Memorial Sloan-Kettering Cancer Center; Newsoara Biopharma
- Class Antineoplastics; Diagnostic agents; Imaging agents; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase I/II Non-small cell lung cancer; Small cell lung cancer
- No development reported Head and neck cancer; Malignant pleural effusion; Solid tumours
Most Recent Events
- 01 Apr 2024 Genelux Corporation plans a phase II trial for Non-small cell lung cancer (Second-line therapy or greater, Recurrent) (IV) in the first half of 2024
- 27 Nov 2023 Olvimulogene nanivacirepvec - Genelux Corporation receives Fast Track designation for Ovarian cancer [Intraperitoneal,Infusion] (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA
- 14 Nov 2023 Phase-I/II clinical trials in Small cell lung cancer (IV) before November 2023